Abstract:Introduction: Genetic testing is a cornerstone in the assessment of many cardiac diseases. However, variants are frequently classified as Variants of Unknown Significance (VUS), limiting the utility of testing. Recently, the DeepMind group (Google, USA) developed AlphaMissense, a unique Artificial Intelligence (AI) based model, based on language model principles for the prediction of missense variant pathogenicity. Objective: To report on the performance of AlphaMissense, accessed by VarCardio, an open web-based variant annotation engine, in a real-world cardiovascular genetics center. Methods: All genetic variants from an inherited arrhythmia program were examined using AlphaMissense via VarCard.io and compared to the ClinVar variant classification system, as well as another variant classification platform (Franklin by Genoox). The mutation reclassification rate and genotype phenotype concordance were examined for all variants in the study. Results: We included 266 patients with heritable cardiac diseases, harboring 339 missense variants. Of those, 230 (67.8%) were classified by ClinVar as either VUS or non-classified. Using VarCard.io, 198 VUSs (86.1%, CI 80.9-90.3%) were reclassified to either Likely Pathgenic (LP) or Likely benign (LB). The reclassification rate was significantly higher for VarCard.io than for Franklin (86.1% vs 34.8%, p<0.001). Genotype-Phenotype concordance was highly aligned using VarCard.io predictions, at 95.9% (CI 92.8-97.9%) concordance rate. For 109 variants classified as Pathogenic, LP, Benign or LB by ClinVar, concordance with VarCard.io was high (90.5%). Conclusion: AlphaMissense, accessed via VarCard.io, may be a highly efficient tool for cardiac genetic variant interpretation. The engine's notable performance in assessing variants that are classified as VUS in ClinVar, demonstrates its potential to enhance cardiac genetic testing. Introduction: Genetic testing is a cornerstone in the assessment of many cardiac diseases. However, variants are frequently classified as Variants of Unknown Significance (VUS), limiting the utility of testing. Recently, the DeepMind group (Google, USA) developed AlphaMissense, a unique Artificial Intelligence (AI) based model, based on language model principles for the prediction of missense variant pathogenicity. Objective: To report on the performance of AlphaMissense, accessed by VarCardio, an open web-based variant annotation engine, in a real-world cardiovascular genetics center. Methods: All genetic variants from an inherited arrhythmia program were examined using AlphaMissense via VarCard.io and compared to the ClinVar variant classification system, as well as another variant classification platform (Franklin by Genoox). The mutation reclassification rate and genotype phenotype concordance were examined for all variants in the study. Results: We included 266 patients with heritable cardiac diseases, harboring 339 missense variants. Of those, 230 (67.8%) were classified by ClinVar as either VUS or non-classified. Using VarCard.io, 198 VUSs (86.1%, CI 80.9-90.3%) were reclassified to either Likely Pathgenic (LP) or Likely benign (LB). The reclassification rate was significantly higher for VarCard.io than for Franklin (86.1% vs 34.8%, p<0.001). Genotype-Phenotype concordance was highly aligned using VarCard.io predictions, at 95.9% (CI 92.8-97.9%) concordance rate. For 109 variants classified as Pathogenic, LP, Benign or LB by ClinVar, concordance with VarCard.io was high (90.5%). Conclusion: AlphaMissense, accessed via VarCard.io, may be a highly efficient tool for cardiac genetic variant interpretation. The engine's notable performance in assessing variants that are classified as VUS in ClinVar, demonstrates its potential to enhance cardiac genetic testing.

Automated variant re-evaluation is labor-balanced and gives clinically relevant results: Hereditary cardiac disease as a use case

The frequency of gene variant reclassification and its impact on clinical management in the inherited arrhythmia clinic

The importance of variant reinterpretation in inherited cardiovascular diseases: Establishing the optimal timeframe

Variant classification changes over time in the clinical molecular diagnostic laboratory setting

Reinterpretation of genetic testing for Cardiomyopathies: Less is more

The Impact of Clinical and Molecular Variant Properties on Calibration and Performance of Variant Effect Prediction Tools

Semiautomated approach focused on new genomic information results in time and effort-efficient reannotation of negative exome data

Evaluation of an Automated Genome Interpretation Model for Rare Disease Routinely Used in a Clinical Genetic Lab

Consultation informs strategies to improve functional evidence use in variant classification

Assessment of variant effect predictors unveils variants difficulty as a critical performance indicator

Performance of a Protein Language Model for Variant Annotation in Cardiac Disease

Implementing a New Algorithm for Reinterpretation of Ambiguous Variants in Genetic Dilated Cardiomyopathy

Accuracy of renovo predictions on variants reclassified over time

Toward Automatic Variant Interpretation: Discordant Genetic Interpretation Across Variant Annotations for ClinVar Pathogenic Variants

Variant reclassification over time decreases the level of diagnostic uncertainty in monogenic obesity: Experience from two centres

Reanalysis of genomic data in rare disease: current practice and attitudes among Australian clinical and laboratory genetics services

Autopvs1: An Automatic Classification Tool For Pvs1 Interpretation Of Null Variants

Abstract 16981: A Machine Learning Model Increases Genetic Confirmation of UKB Participants With Suspected Monogenic Cardiovascular Disease

Reanalysis of genomic data, how do we do it now and what if we automate it? A qualitative study

CAVaLRi: An Algorithm for Rapid Identification of Diagnostic Germline Variation

Comparison of the ABC and ACMG systems for variant classification